Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Establish the Feasibility of Enolen (tm) for the Local Delivery of Enzalutamide in Patients With Prostate Cancer

NCT06257693 is registered in ClinicalTrials.gov with Alessa Therapeutics Inc. as lead sponsor.

NCT NCT06257693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06257693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Establish the Feasibility of Enolen (tm) for the Local Delivery of Enzalutamide in Patients With Prostate Cancer
Lead sponsor
Alessa Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 21, 2024
Completion date
December 30, 2028
Enrollment
45 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma